Aduro Biotech, Inc. (NASDAQ:ADRO) – Investment analysts at Oppenheimer Holdings issued their FY2017 EPS estimates for Aduro Biotech in a report issued on Monday, Zacks Investment Research reports. Oppenheimer Holdings analyst M. Breidenbach forecasts that the biotechnology company will post earnings per share of ($1.38) for the year. Oppenheimer Holdings currently has a “Buy” rating and a $15.00 target price on the stock. Oppenheimer Holdings also issued estimates for Aduro Biotech’s Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.42) EPS, Q3 2018 earnings at ($0.43) EPS, Q4 2018 earnings at ($0.42) EPS, FY2018 earnings at ($1.67) EPS, FY2019 earnings at ($1.90) EPS and FY2021 earnings at ($0.78) EPS.
A number of other equities research analysts have also recently issued reports on the company. HC Wainwright set a $18.00 target price on Aduro Biotech and gave the stock a “buy” rating in a research report on Wednesday, November 1st. William Blair reissued an “outperform” rating on shares of Aduro Biotech in a research report on Monday, October 2nd. BidaskClub cut Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research cut Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.14.
COPYRIGHT VIOLATION NOTICE: “Aduro Biotech, Inc. to Post FY2017 Earnings of ($1.38) Per Share, Oppenheimer Holdings Forecasts (NASDAQ:ADRO)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/brokers-set-expectations-for-aduro-biotech-inc-s-fy2017-earnings-adro.html.
Shares of Aduro Biotech (ADRO) opened at $7.95 on Thursday. Aduro Biotech has a 12-month low of $6.01 and a 12-month high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The company had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.54) EPS.
Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc lifted its position in Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 1,043 shares during the period. Fox Run Management L.L.C. bought a new position in Aduro Biotech in the third quarter worth $127,000. Tudor Investment Corp ET AL lifted its position in Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 3,984 shares during the period. Parametric Portfolio Associates LLC lifted its position in Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 2,119 shares during the period. Finally, SG Americas Securities LLC bought a new position in Aduro Biotech in the third quarter worth $167,000. 34.01% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Stephen T. Isaacs sold 20,200 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $7.98, for a total value of $161,196.00. Following the completion of the transaction, the insider now directly owns 190,321 shares of the company’s stock, valued at $1,518,761.58. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Gregory W. Schafer sold 20,000 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $7.97, for a total value of $159,400.00. Following the completion of the transaction, the chief operating officer now directly owns 155,677 shares of the company’s stock, valued at $1,240,745.69. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 173,745 shares of company stock valued at $1,782,876. 6.60% of the stock is owned by company insiders.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Get a free copy of the Zacks research report on Aduro Biotech (ADRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.